
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Amylyx Pharmaceuticals Inc (AMLX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: AMLX (4-star) is a STRONG-BUY. BUY since 47 days. Profits (46.96%). Updated daily EoD!
1 Year Target Price $12.62
1 Year Target Price $12.62
5 | Strong Buy |
1 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -11.42% | Avg. Invested days 55 | Today’s Advisory Strong Buy |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 839.96M USD | Price to earnings Ratio - | 1Y Target Price 12.62 |
Price to earnings Ratio - | 1Y Target Price 12.62 | ||
Volume (30-day avg) 7 | Beta -0.45 | 52 Weeks Range 2.08 - 9.72 | Updated Date 08/29/2025 |
52 Weeks Range 2.08 - 9.72 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.49 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.46 | Actual -0.46 |
Profitability
Profit Margin - | Operating Margin (TTM) 79106.43% |
Management Effectiveness
Return on Assets (TTM) -46.74% | Return on Equity (TTM) -87.42% |
Valuation
Trailing PE - | Forward PE 2.77 | Enterprise Value 665093209 | Price to Sales(TTM) 4.44 |
Enterprise Value 665093209 | Price to Sales(TTM) 4.44 | ||
Enterprise Value to Revenue 6446.63 | Enterprise Value to EBITDA -11.71 | Shares Outstanding 89167400 | Shares Floating 47960487 |
Shares Outstanding 89167400 | Shares Floating 47960487 | ||
Percent Insiders 9.5 | Percent Institutions 94.65 |
Upturn AI SWOT
Amylyx Pharmaceuticals Inc

Company Overview
History and Background
Amylyx Pharmaceuticals, Inc. was founded in 2013 by Justin Klee and Joshua Cohen. It focuses on developing treatments for neurodegenerative diseases. The company's early focus was on identifying novel therapies for ALS. A key milestone was the approval of Relyvrio for ALS in the US.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Develops and commercializes therapies for neurodegenerative diseases, with a primary focus on Amyotrophic Lateral Sclerosis (ALS).
Leadership and Structure
Joshua Cohen and Justin Klee serve as co-CEOs. The company has a board of directors and a management team overseeing research, development, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Relyvrio (sodium phenylbutyrate and taurursodiol): Relyvrio is a combination drug approved for the treatment of ALS. While precise market share data is difficult to ascertain due to limited treatment options, Relyvrio aims to address the disease's unmet need. Competitors include generic riluzole and edaravone (Radicava), both approved therapies for ALS.
Market Dynamics
Industry Overview
The pharmaceutical industry focusing on neurodegenerative diseases is characterized by high unmet needs and significant R&D investment. ALS, in particular, has limited treatment options.
Positioning
Amylyx is positioned as a company specializing in ALS therapeutics with an FDA-approved product. Its competitive advantage lies in Relyvrio, one of the few approved treatments for the disease.
Total Addressable Market (TAM)
The TAM for ALS therapeutics is estimated to be in the billions of dollars, given the high cost of treatment and the prevalence of the disease. Amylyx is positioned to capture a significant portion of this TAM with Relyvrio.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Relyvrio)
- Focused on a high-need area (ALS)
- Experienced leadership team
Weaknesses
- Limited product pipeline
- Reliance on a single product for revenue
- Relatively small company size
Opportunities
- Expansion of Relyvrio to other markets (e.g., Europe)
- Development of new therapies for ALS and other neurodegenerative diseases
- Partnerships and acquisitions
Threats
- Competition from other ALS therapies
- Regulatory hurdles
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- ITCI
- MTNB
- IONS
Competitive Landscape
Amylyx has a competitive advantage with Relyvrio's approval, but faces competition from established pharmaceutical companies. The company's success depends on its ability to effectively commercialize Relyvrio and develop new therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is linked to the development and approval of Relyvrio, but quantitative data requires access to specific financial reports.
Future Projections: Future projections depend on Relyvrio sales, market expansion, and pipeline development. Analyst estimates change frequently.
Recent Initiatives: Recent initiatives include expanding access to Relyvrio, conducting post-marketing studies, and advancing pipeline programs.
Summary
Amylyx is a pharmaceutical company with an approved therapy, Relyvrio, for ALS, positioning it well in a high-need market. Its reliance on a single product makes it vulnerable, and successful commercialization of Relyvrio and pipeline expansion are crucial for long-term growth. Competition in the neurodegenerative disease space presents an ongoing threat. Amylyx needs to look to additional drug development to improve its financial outlook.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amylyx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2022-01-07 | Co-Founder, Co-CEO & Director Mr. Joshua B. Cohen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://amylyx.com |
Full time employees 123 | Website https://amylyx.com |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.